Expanded Access Program for CT1812 (Zervimesine)

NO_LONGER_AVAILABLE

Conditions studied: Dementia With Lewy Bodies

In brief

This is a multi-center, open label, expanded access program (EAP) that will provide 100 mg CT1812 for up to one year to participants with mild-to-moderate DLB.

Key facts

Study ID

NCT06961760

Run by

Cognition Therapeutics

Last updated by the study team

2026-05-28

Who can join

Age: 50 and older, up to 86. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must meet either one of the following criteria:
• Randomized participant in protocol COG1201 and completed the study or
• Referred by their treating physician to a participating COG1202 study site with a confirmed diagnosis of probable DLB, provide evidence of a historical MRI (within last 3 months) or CT-Scan (within last 3 months), a baseline Mini Mental Status Examination score (MMSE) of 18 - 27 inclusive and be approved by Sponsor
• Participants must have caregiver(s) / study partner who in the opinion of the site principal investigator, has contact with the study participant for a sufficient number of hours per week to provide informative responses on the protocol assessments, oversee the administration of study drug, and willing and able to participate in study visits and some study assessments. The caregiver/ study partner must also provide informed consent to participate in the study.
• Men or women 50- 86 years of age (inclusive).
• Must have had no clinically relevant findings, other than change for progression of DLB, on historical MRI or CT scan.
• In the opinion of the investigator, must be able to complete all protocol evaluations.

You may not qualify if…

• If enrolled in the previous CT1812 clinical trial for DLB (COG1201), did not complete the clinical trial, or had an adverse event that could cause an undue risk, or progressed to severe DLB and cannot complete study assessments.
• Any neurological condition that may be contributing to cognitive impairment and beyond those caused by the participant's DLB.
• History of cancer within 3 years of screening with the exception of fully excised non-melanoma skin cancers or non-metastatic prostate cancer that has been stable for at least 6 months based on imaging or Prostate-Specific Antigen (PSA) levels.
• Clinically significant, advanced or unstable disease that may interfere with outcome evaluations.
• Any condition, which in the opinion of the investigator or the sponsor makes the participant unsuitable for inclusion.
• No access to a Primary Care Physician, inability or unwillingness to have lab sample collection completed per protocol.

Where it is running

• Banner Sun Health Research Institute — Sun City, Arizona, United States
• Stanford Neuroscience Heath Center — Palo Alto, California, United States
• University of Colorado Denver - Anschutz Medical Campus — Aurora, Colorado, United States
• University of Miami - Department of Neurology — Boca Raton, Florida, United States
• Mayo Clinic - Rochester — Rochester, Minnesota, United States
• Columbia University Medical Center — New York, New York, United States
• Ohio State University Wexner Medical Center (OSUWMC) — Columbus, Ohio, United States
• Summit Headlands LLC — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.